Brief: Island Pharmaceuticals Says FDA Grants Orphan Designation For Galidesivir In Marburg
17/06/2026 02:43
BRIEF-Island Pharmaceuticals Says FDA Grants Orphan Designation For Galidesivir In Marburg June 17 (Reuters) - Island Pharmaceuticals Ltd ILA.AX:
FDA GRANTS ORPHAN DESIGNATION FOR GALIDESIVIR IN MARBURG
FDA GRANTS ORPHAN DRUG DESIGNATION TO GALIDESIVIR FOR MARBURG VIRUS DISEASE
Further company coverage: ILA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic